Mucosolvan (Ambroxol Hydrochloride)

Ambroxol Hydrochloride works by stimulating the production of pulmonary surfactant and enhancing the activity of cilia in the respiratory tract. It breaks down mucopolysaccharide fibers in mucus, reducing its viscosity, while the increased surfactant lowers surface tension, together promoting more efficient mucociliary clearance.

The appropriate dose of Mucosolvan is determined by a qualified healthcare professional based on the patient’s age, clinical condition, and response to therapy. Prescribers tailor the regimen to achieve optimal mucus clearance while minimizing potential side effects.

Safety data for Ambroxol Hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the Mucosolvan product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mucosolvan (Ambroxol) differs from other mucolytics such as N‑acetylcysteine by primarily stimulating surfactant production and ciliary activity, whereas N‑acetylcysteine acts mainly by breaking disulfide bonds in mucus. Both improve sputum clearance, but Ambroxol’s additional surfactant effect may provide a smoother expectoration experience for some patients.

Mucosolvan should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Mucosolvan is taken orally, usually as a tablet or liquid formulation, according to the prescribing information. It is generally swallowed with a glass of water and can be taken with or without food, depending on the specific product instructions provided by the prescriber.

Serious adverse reactions, although rare, include allergic responses such as hives, facial swelling, or difficulty breathing, which require immediate medical attention. Rare but severe skin conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis have also been reported and should be promptly reported to a healthcare professional.

Mucosolvan should be avoided in individuals with known hypersensitivity to ambroxol or any excipients in the formulation. Patients with severe renal impairment may need dose adjustment, and those with uncontrolled asthma should use it only under medical supervision due to the potential for bronchospasm.